CTDH News and Press, Ctd Holdings Inc From 10/09/19

Reena Sharma, MD will serve as EU Coordinating Investigator for Extension Protocol Cyclo Therapeutics, Inc. (OTCQB: CTDH), formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced ...

Cyclo Therapeutics ( OTCQB:CTDH -2.3% ) has completed its name change from CTD Holdings. More news on: CTD Holdings, Inc., Read more ...

Cyclo Therapeutics, Inc. (OTCQB: CTDH) announced today that it has completed its name change from CTD Holdings, Inc. following appropriate regulatory filings with the State of Florida and FINRA. The new name better reflects the company’s business as a biotechnology company that develop...

VPR Brands specializes in vaporizers & accessories for essential oils, cannabis concentrates and extracts (CBD), and e-cigarettes containing nicotine The company’s assets include issued U.S. and Chinese patents for atomization-related products VPR Brands CEO, President and Ch...

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced a new collaboration with the Chattanooga Center for Neurologic Research (CCNR) based in Chattanooga, TN. CCN...

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will provide Trappsol ® Cyclo™, its proprietary hydroxypropyl beta cyclodextri...

CTD is also a proud sponsor of the conference, for the 4 th year running CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will present...

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today an interview with Company Chair and CEO N. Scott Fine will air on The RedChip Money Report television ...

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that it held a meeting of shareholders in New York City for the purpose of approving three proposals, al...

CTD presentation to take place at the National Niemann-Pick Disease Foundation Conference August 16, 2019 CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today poste...